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CASE PRESENTATION
A 28 year old man was brought to the hospital by
ambulance complaining of ‘ringing in his ears’ and
dyspnea. He reports ingesting a ‘whole bottle’ of aspirin
four hours prior to admission in a suicide attempt.
Upon presentation to the hospital, he was alert and
oriented and was slightly agitated. He denied any other
co-ingestion. His initial blood pressure was 128/70 mmHg
with a regular heart rate of 110/min. His respiratory rate
was 24/min, slightly labored, O2 saturation 98%, and his
oral temperature was 98.6 1F (37.0 1C). His pupils were
equal, round, and reactive to light, cardiac exam was
normal other than tachycardia, and his lungs were clear to
auscultation bilaterally. The remainder of his physical
exam was unremarkable. He weighed 155 lbs (70.5 kg).
Chest X-ray was normal and electrocardiogram revealed
sinus tachycardia at 110/min. Admission serum laboratory
values are shown in Table 1. Complete blood counts as
well as pancreatic and hepatic enzymes were all within
normal limits. Urinalysis showed a pH of 6.1 and 1þ
ketones but was otherwise unremarkable. A urine
toxicology screen confirmed the absence of barbiturates,
opiates, cocaine, as well as tricyclic antidepressants. Serum
toxicology revealed the presence of salicylate, and
confirmed the absence of acetaminophen and ethanol.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of a patient with tachypnea and
altered mental status is quite broad and includes cardiac or
pulmonary disease with resulting hypoxia, sepsis, neurologi-
cal dysfunction, and toxic/metabolic syndromes including
poisoning. In this case, the presence of tinnitus, respiratory
alkalosis, and an elevated anion gap (implying concurrent
metabolic acidosis) coupled with a known ingestion of
aspirin made the diagnosis relatively straightforward.
CLINICAL FOLLOW-UP
Activated charcoal (1 gm/kg orally) was administered. It was
then followed by intravenous hypertonic sodium bicarbonate
(8.4%) as a bolus of two ampules (89 mEq; approximately
1 mEq/kg), followed by a continuous intravenous infusion of
sodium bicarbonate, containing three ampules (134 mEq) of
8.4% sodium bicarbonate in 1 l of 5% dextrose in water
(D5W), delivered at a rate of 200 ml/h. Two hours later, the
patient became diaphoretic, tachypneic, more agitated, and
complained of respiratory distress. His vital signs were blood
pressure 140/70 mmHg, heart rate of 120/min, respiratory
rate of 32/min, O2 saturation 92%, and an oral temperature
of 100.2 1F (37.9 1C). The patient was given 10 mg of
intravenous diazepam for sedation, which resulted in
worsening of his respiratory distress. After two failed
intubation attempts, he successfully underwent rapid se-
quence endotracheal intubation followed by mechanical
ventilation with a tidal volume setting of 700 ml, a rate of
16/min and a FiO2 of 100%. He was transferred to the
intensive care unit. Repeat arterial blood gasses are shown in
Table 1. One hour after transfer, his electrocardiogram
revealed pulseless electrical activity. Attempts at resuscitation
were unsuccessful and the patient expired.
This case highlights some of the pitfalls in managing a
patient who presents with acute salicylate poisoning.
DISCUSSION
Salicylate poisoning may be somewhat artificially divided
into acute and chronic clinical syndromes, differing largely by
the degree to which the clinical findings manifest. Both
syndromes are associated with gastrointestinal distress,
neurological effects, and metabolic abnormalities. Salicylate
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(the metabolite of aspirin) is a metabolic poison that affects
many organ systems, the most consequential of which is the
central nervous system (CNS). Common neurological
manifestations of salicylism include tinnitus, altered mental
status, and respiratory alkalosis. Respiratory alkalosis is the
result of sensitization of the medullary respiratory center to
CO2. Cerebral edema, which can be fatal, occurs in patients
with more severe poisoning, and is the reason that this
diagnosis should be considered and then managed expedi-
tiously. An altered mental status not completely explained by
another cause mandates an aggressive management strategy.
Salicylate poisoned patients develop an anion gap metabolic
acidosis which, like hyperthermia, is the result of uncoupling
of mitochondrial oxidative phosphorylation. The unmea-
sured anions include a mixture of lactate, salicylate (and
metabolites), and ketoacids.
Epidemiology
In 2004, there were 2.4 million cases of human poisoning
reported to the American Association of Poison Control
Centers.1 Analgesics were the most frequently involved single
category. Products containing salicylates accounted for
greater than 20,000 exposures and more than 10% of deaths
associated with analgesics. This is not a new phenomenon. A
review in the 1980s showed that salicylates were the most
common agent responsible for single drug-induced death in
Ontario.2 In England, they accounted for 10% of adult
hospital admissions for deliberate self-poisonings.3 Many
common medical and psychiatric presentations (Table 2) can
actually be the result of undiagnosed aspirin poisoning.4
Thus, the data may underestimate the true incidence of
aspirin poisoning.
Salicylate poisoning has been a consistent source of
referral to medical professionals and accounts for significant
morbidity and mortality. Yet the management of aspirin
poisoning remains a rare event for the vast majority of
clinicians. When added to the complex pharmacology and
nonintuitive pathophysiologic effects of aspirin in overdose,
there are recurrent pitfalls that are well reported in specialty
textbooks, but may not be familiar to most nephrologists. We
will review some of these issues in this consult article. A more
in depth guide to salicylate poisoning and its management
can be found in medical toxicology textbooks.5
Serum salicylate concentrations
Prompt treatment is aimed at keeping salicylate out of the
most vulnerable organ, the CNS.6 Although urinary alkali-
nization traps dissociated acetylsalicylate (pK 3.5) and
salicylate (pK 3.0)7 and promotes urinary excretion, alkali-
nization of serum will, more importantly, promote move-
ment of salicylate from tissues (e.g. CNS) into serum and
diminish toxicity. A more acidic extracellular pH, which
results from a frequently concomitant metabolic acidosis
(because of uncoupled oxidative phosphorylation), is asso-
ciated with enhanced entry of salicylate into the CNS. Under
these conditions, salicylate is protonated in the serum into its
nonionized, lipid soluble form, which can passively cross the
blood–brain barrier and cause CNS injury.8
In assessing the severity of salicylate poisoning, many
practitioners rely inappropriately on serum salicylate levels to
make treatment decisions. Interpretation of serum salicylate
concentrations is complex and must be viewed in the context
of the serum pH.9 As the blood pH falls, the volume of
distribution of salicylate rises as it diffuses out of the serum
and into tissues. Falling serum salicylate concentrations can
then be a harbinger of decompensation and can only be used
as a sign of therapeutic success in the context of improved
clinical status, verified renal excretion, or extracorporeal
removal.6 Rising serum salicylate concentrations, from
whatever starting point, can be equally unsettling as they
most often indicate continuing intestinal absorption.10
Chronic salicylate poisoning occurs with lower serum
concentrations, often in the high end of the therapeutic
range, and judgment regarding the time course in an
Table 1 | Laboratory data2
Serum electrolytes
Reference
range
Initial
value
Post
intubation
Sodium (mEq/l) 137–145 140 146
Potassium (mEq/l) 3.6–5.0 2.8 3.2
Chloride (mEq/l) 98–107 100 110
Bicarbonate (mEq/l) 22–30 18 22
Anion gap (mEq/l) 8–12 22 14
Creatinine (mg/100 ml) 0.6–1.5 1.0 1.0
Blood urea nitrogen (mg/100 ml) 10–24 10 11
Glucose (mg/100 ml) 70–110 100 94
Serum APAP (mcg/ml) o20 0 NA
Serum salicylate (mg/100 ml) 2.0–19.9 35 85
Serum alcohol (mg/100 ml) o10.0 0 NA
Blood gas
pH 7.35–7.45 7.50 7.22
PCO2 (mmHg) 35–45 20 48
PO2 (mmHg) 80–100 125 140
APAP, acetaminophen; NA, not available.
Table 2 | Features of salicylate poisoning
CNS Signs and symptoms Laboratory findings
Hyperactivity Nausea/vomiting Respiratory alkalosis
Irritability Tinnitus/hearing loss Anion gap metabolic
acidosis
Agitation Hyperventilation
(tachypnea and/or hyperpnea)
Urinary ketones
Vertigo Hyperkalemia
Slurred speech Mild hyperlactatemia
Delirium Pulmonary edema Coagulation
abnormalities
Hallucinations Hyperthermia
Tachycardia
Lethargy Volume depletion
Stupor Arrhythmias
Seizures Diaphoresis
Coma
Cerebral edema
CNS, central nervous system.
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individual patient is not always accurate. ‘Chronic’ poisoning
does not necessarily require a long-term exposure; it is more
accurately a pharmacological state in which the tissue burden
is high and at near steady state, as opposed to ‘acute’ or early
exposures, in which the tissue burden is low and/or rising.
Although many authors have offered classifications of
clinical severity based on serum concentrations, there is little
consensus, and these categories are notoriously difficult to
link to recommended therapies or expected outcomes. In
relying heavily on serum concentrations, underdiagnosis of
poisoning severity is common and morbidity and mortality
may be the result. Serum salicylate concentrations should be
interpreted in the context of the acuity of the exposure, the
serum pH, and the overall clinical condition. The diagnosis
of poisoning, a judgment regarding its severity, and the
decision to perform hemodialysis are based on the clinical
findings, particularly assessment of the CNS and acid–base
status. Serum salicylate concentrations are at best an adjunct
to this assessment.
Treatment
There is no antidote for salicylate poisoning. Treatment is
directed toward preventing further intestinal absorption of
the drug, preventing its entry into the CNS, enhancing
removal of drug from CNS, and hastening elimination of the
drug from the body. Gastric lavage immediately following
ingestion, while controversial, has been recommended.11,12
However, it is not a definitive treatment because it is of
unpredictable efficacy and does little to hasten elimination of
already absorbed salicylate, and thus is not used often.3 Oral-
activated charcoal suffers similar limitations, but given its
more favorable risk/benefit relationship, is still widely
administered when felt safe to do so.12 For many years
forced diuresis, by rapidly administering large volumes of
normal saline intravenously, was widely used. It has fallen out
of favor due to its lack of proven benefit, the potential for
fluid and electrolyte abnormalities, and the risk of pulmonary
edema in severely salicylate-poisoned patients. Administra-
tion of saline is only appropriate to replete extracellular fluid
volume in patients with acute decreases in glomerular
filtration rates.
The most widely used and first line of treatment involves
the administration of hypertonic sodium bicarbonate.
Although traditionally considered a means of alkalinizing
the patient’s urine to trap ionized salicylate in the renal
tubules and promote the drug’s excretion, it is likely more
important due to its ability to alkalinize the serum and
promote transfer of the drug out of the CNS. Although
extensively studied, there are no randomized controlled trials
to guide its appropriate use and gauge its efficacy. The safety
and utility of inducing metabolic alkalosis in cases in which
salicylate-induced respiratory alkalosis predominates over
metabolic acidosis, or in people with diminished glomerular
filtration rates, is not established. There are also no published
evidence-based guidelines for the use of sodium bicarbonate.
Much of the literature regarding its use is based on case
reports and animal models of salicylate poisoning. Many have
reported successful resolution of symptoms, but inadequate
dosing and inconsistent results remains a concern. It is also
unknown what role serum salicylate and electrolyte concen-
trations, acid–base status, hemodynamic status, and general
state of health involve in determining the systemic and
urinary response to alkalinization therapy.
Despite questions about its mechanism and optimal
application,13 it is appropriate to start alkalinizing the
patient’s serum and urine on presentation to the hospital.
However, hemodialysis, the definitive method for removing
salicylates, should also be considered without delay, due to
both the variable clinical course and the unpredictability of
response to alkalinization. The potential for rapid decom-
pensation should be recognized, and may be due to
continued, prolonged intestinal absorption, respiratory
decompensation, or acute worsening of metabolic acidosis.
Hemodialysis
Diverse and inconsistent recommendations regarding initia-
tion of hemodialysis, based on serum salicylate concentra-
tions, have been proposed. As low serum levels are unreliable
in assessing severity, we find these level-based recommenda-
tions unreliable. Data from the American Association of
Poison Control Centers in 2004 show that only half of the
fatal acute cases reported ever had salicylate concentrations
that exceeded 100 mg/100 ml, with some in the 50–70 mg/
100 ml range.1 Although these data may not adequately
distinguish acute from chronic poisonings, and have a variety
of flaws in the ascertainment and reporting procedures, they
suggest that current assessment of severity based on serum
concentrations needs to be reconsidered. The data from
Ontario 2 showed similar findings and are shown in Table 3.
Clearly, patients die with less dramatically elevated serum
concentrations than many clinicians have been taught to
expect.
Regarding the deaths in Ontario, the authors commented
that ‘it is remarkable that none of the patients (in their
sample) received hemodialysis’.2 Many of the patients in the
‘alert’ mental status group lived long enough to be transferred
to an appropriate facility with dialysis capability, but were
not dialyzed. Other patients died in a hospital where
hemodialysis could have been performed without transfer.
Similarly the authors of the American Association of Poison
Control Centers report state, as they have in the past, that
most of the fatalities did not receive dialysis in an appropriate
time frame.1,14 They concluded that these data suggest that
more aggressive and earlier use of dialysis may be indicated in
the treatment of clinically significant salicylate ingestions.
Given the difficulties with interpretation of serum
concentrations, the real risk of adverse consequences, and
the exhortation of experts that dialysis is underutilized, a
reliance solely on serum concentrations should be aban-
doned. Although patients with high serum salicylate
concentrations (e.g., 4100 mg/100 ml) may clearly warrant
empiric hemodialysis regardless of their immediate clinical
Kidney International (2009) 75, 1349–1353 1351
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condition, many patients with lower concentration who are
symptomatic do as well. A robust clinical evaluation should
instead be employed in recommending its use. Serum
concentrations are most appropriately used to confirm the
diagnosis of salicylate poisoning and for judging the
effectiveness of therapy designed to enhance the elimination
of salicylate.
Dialysis should be performed in patients with CNS
toxicity, especially when combined with other organ
dysfunction, particularly in the setting of decreased glomer-
ular filtration rates. As salicylates are metabolized in the liver
and excreted by the kidneys, patients with hepatic or renal
dysfunction often require prompt hemodialysis. In the
presence of signs of CNS toxicity (such as drowsiness or
agitation), or severe hyperventilation (PCO2p25 mm/Hg) as
in this case, one should not wait until further acute
deterioration occurs before considering hemodialysis. Other
findings that may warrant dialysis are listed in Table 4.
Deleterious consequences often result from intubation and
mechanical ventilation in salicylate-poisoned patients as
occurred in this case.15 Healthcare providers often do not
maintain the appropriate level of hyperventilation that is
necessary to maintain hypocarbia and a beneficial pH
balance.5 Ventilator settings are often inadequate to duplicate
the patients’ own required respiratory effort, resulting in
hypoventilation. Hyperventilation and hypocarbia cause
alkalemia, which in turn is protective of the CNS.16 An
increase in PCO2 can result from inadequate ventilation, with
a consequent respiratory acidosis. The effect of the resultant
acidemia is the conversion of salicylate (charged) to salicylic
acid (uncharged), with subsequent passive movement of the
acid into the CNS, resulting in clinical deterioration. Thus,
prompt hemodialysis is preferred to, or should at least be
coincident with, instituting ventilatory support when salicy-
late poisoning is cited as an indication for intubation. When
intubation is clearly indicated in a salicylate poisoned patient,
regardless of the actual reason for the procedure, the initial
ventilator settings should strive for minute volumes far
beyond those usually calculated from age- and weight-based
nomograms. Patients at extremes of age, or those who present
with severe systemic metabolic acidosis or pulmonary edema
should also be treated with hemodialysis.10
In this case, the ventilators’ initial low tidal volume and
low respiratory rate was inadequate to maintain an alkalemic
pH. Higher tidal volumes and respiratory rate were needed to
mimic what this previously healthy, young man was able to
achieve by hyperventilating. PCO2 rose and the resultant
respiratory acidosis, superimposed on the salicylate-induced
metabolic acidosis, caused a redistribution of salicylate into
the CNS, likely contributing to the patient’s demise.
Prompt hemodialysis
Physicians, whether emergency medicine specialists or
nephrologists, are often hesitant about the use of hemodia-
lysis and prefer to initially use less dramatic methods. This
case illustrates the pitfalls of attempting to alkalinize the
serum and urine or waiting for serum salicylate salicylate
results. Although it is prudent and easy to initiate attempts to
promptly alkalinize the urine, it should not be seen as a
substitute for hemodialysis in potentially severe cases.
Hemodialysis should be promptly considered because there
are intrinsic delays to its immediate performance. Depending
on the time of day staff may have to be summoned, a
machine prepared, a dialysis ‘slot’ opened, and venous access
established. Prompt consultation with the nephrology service
is mandatory, and nephrologists should view hemodialysis as
likely indicated for moderately to severely symptomatic
patients.
Extracorporeal removal of salicylates is efficient because
both the drug’s molecular weight, 138 Da (aspirin, acetylsa-
licylic acid 180), and its apparent volume of distribution,
0.2 l/kg, are relatively small.17 Protein binding at therapeutic
doses is about 90%, a property which would favor charcoal
hemoperfusion over hemodialysis. At higher serum levels
however, the proportion of total salicylate that is free and not
protein-bound increases, making hemodialysis more effica-
cious at toxic levels.18 Although charcoal hemoperfusion is
relatively inexpensive, easy to use,6 and results in better
salicylate clearance, hemodialysis is the procedure of choice
Table 3 | Data from Ontario showing serum salicylate concentrations in selected patients
Total
number in
category
Number of patients
who underwent
premortem testing
Mean premortem
salicylate concentrations
(mg/100 ml)
Number of patients
who underwent
postmortem testing
Mean postmortem
salicylate concentrations
(mg/100 ml)
Death prior to medical intervention 16 16 51 (range 17–101)
Presented with coma 11 10 80 (range 34–137) 2 68 and 33
Presented in ‘alert status’ 23 7 97 (range 61–193) 12 66 (range 36–130)
Table 4 | Findings that should prompt consideration of
hemodialysis
K Markedly elevated serum concentrations (4100 mg/100 ml), even
without clinical findingsa
K Serum concentrations in or above therapeutic range and
- CNS dysfunction (e.g. delirium, lethargy, seizures, coma) with no
other explanation
- Renal failure
- Pulmonary edema/hypoxia
- Severe acid–base or electrolyte imbalance with no other
explanation
CNS, central nervous system.
aIt is important to compare the serum concentration with the patient’s history and
other corroborating clinical/laboratory data to avoid error caused by laboratory or
unit conversion misinterpretations.22
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because of its ability to rapidly correct acid–base and
electrolyte abnormalities.8,19 Our recent study showed that
hemoperfusion is currently unavailable at most hospitals
taking ambulance calls.20
Detailed recommendations regarding hemodialysis proto-
cols for salicylate intoxication are not available and consist of
anecdotal reports. Utilizing techniques familiar to nephrol-
ogists from the treatment of acute kidney injury, excellent
salicylate clearance can be achieved. Our goal is blood flow
rate of 350–400 ml/min for at least 3.5–4 h. We use
biocompatible hemodialysis membranes with larger surface
areas; high flux membranes are unlikely to cause clinically
meaningful increases in clearance of a relatively low
molecular weight molecule. Reassessment of salicylate levels,
the patient’s signs and symptoms, and response to continuing
urinary alkalinization will determine if a second hemodialysis
treatment is indicated.
Recent reports have demonstrated efficacy for treatment
of poisonings with continuous venovenous hemofiltration,
which is widely available in many intensive care units.
However, it is relatively slower than hemodialysis and may
not address promptly enough the needs of more severe
cases.21 In a series of three case reports, patients were treated
with continuous venovenous hemodiafiltration, a technique
in which addition of dialysate adds diffusive clearance to the
less efficient convective clearance of continuous venovenous
hemofiltration.18 A more rapid benefit than might have been
expected was demonstrated. No controlled trials comparing
continuous venovenous hemofiltration with hemodialysis
have been made. Despite its relatively slower clearance rates,
continuous venovenous hemofiltration may be useful in cases
of severe salicylate poisoning when conventional hemodia-
lysis is unavailable or in patients who are too hemodynami-
cally unstable for hemodialysis. When available, hemodialysis
is the method of choice.18,21
CONCLUSION
Poison control centers and medical toxicologists must
maintain active working relationships with nephrologists
and vice versa. In this case of aspirin poisoning, a delay in the
initiation of hemodialysis is a potentially preventable cause of
death. Aspirin overdose with its complications of hemody-
namic, electrolyte, and acid–base issues, is best managed in
consultation with a nephrologist. At the New York City
Poison Control Center, nephrologists attend monthly case
conferences and are routinely involved in the consultation
and care of poisoned patients. There are a number of toxins
for which definitive and life-saving treatment is hemodialysis.
In the setting of 20 years of repeated calls by experts for a
more liberal application of hemodialysis for salicylate
poisoning, it is unacceptable that patients are not undergoing
prompt hemodialysis. Nephrologists should be consulted
promptly and should respond promptly to requests for
consultation. With the active involvement of nephrologists,
and nephrologists’ early intervention, many deaths from
salicylate poisoning will be prevented.
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